Healthcare provider profile · identity verified

Sara Sadat, D.O.

Internal Medicine · WOODLAND HILLS, CA · NPI 1508202649

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	434	161
Rosuvastatin Calcium	Rosuvastatin Calcium	283	107
Amlodipine Besylate	Amlodipine Besylate	258	99
Lisinopril	Lisinopril	236	88
Levothyroxine Sodium	Levothyroxine Sodium	224	79
Losartan Potassium	Losartan Potassium	209	77
Albuterol Sulfate Hfa	Albuterol Sulfate	146	77
Gabapentin	Gabapentin	132	49
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	131	28
Simvastatin	Simvastatin	126	48
Alendronate Sodium	Alendronate Sodium	117	47
Atenolol	Atenolol	115	43
Furosemide	Furosemide	108	34
Metformin Hcl Er	Metformin Hcl	108	37
Metoprolol Tartrate	Metoprolol Tartrate	104	35
Hydrochlorothiazide	Hydrochlorothiazide	103	36
Metformin Hcl	Metformin Hcl	90	35
Omeprazole	Omeprazole	88	40
Potassium Chloride	Potassium Chloride	83	29
Tamsulosin Hcl	Tamsulosin Hcl	83	32
Trazodone Hcl	Trazodone Hcl	71	25
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	60	23
Carvedilol	Carvedilol	56	12
Glipizide	Glipizide	53	23
Acetaminophen-Codeine	Acetaminophen With Codeine	51	22
Terazosin Hcl	Terazosin Hcl	48	19
Temazepam	Temazepam	46	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	45	14
Triamcinolone Acetonide	Triamcinolone Acetonide	45	32
Hydrocortisone	Hydrocortisone	43	19
Prednisone	Prednisone	43	38
Famotidine	Famotidine	39	13
Sertraline Hcl	Sertraline Hcl	37	15
Pantoprazole Sodium	Pantoprazole Sodium	36	19
Mupirocin	Mupirocin	35	21
Escitalopram Oxalate	Escitalopram Oxalate	34	14
Estradiol	Estradiol	34	17
Fluoxetine Hcl	Fluoxetine Hcl	34	12
Ondansetron Odt	Ondansetron	34	11
Cefadroxil	Cefadroxil	33	27
Clopidogrel	Clopidogrel Bisulfate	33	15
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	32	suppressed
Ezetimibe	Ezetimibe	28	suppressed
Jardiance	Empagliflozin	27	11
Alvesco	Ciclesonide	25	20
Eliquis	Apixaban	25	suppressed
Finasteride	Finasteride	25	suppressed
Lorazepam	Lorazepam	25	11
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Hydralazine Hcl	Hydralazine Hcl	24	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	24	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	23	23
Allopurinol	Allopurinol	23	suppressed
Alprazolam	Alprazolam	22	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	22	21
Acyclovir	Acyclovir	21	14
Buspirone Hcl	Buspirone Hcl	21	suppressed
Montelukast Sodium	Montelukast Sodium	21	suppressed
Clonazepam	Clonazepam	20	suppressed
Diazepam	Diazepam	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Citalopram Hbr	Citalopram Hydrobromide	19	suppressed
Colchicine	Colchicine	19	suppressed
Mirtazapine	Mirtazapine	19	suppressed
Spironolactone	Spironolactone	19	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Nystatin	Nystatin	18	13
Humulin N Kwikpen	Insulin Nph Human Isophane	17	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	16	16
Baclofen	Baclofen	16	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	16	16
Azithromycin	Azithromycin	15	15
Meloxicam	Meloxicam	15	14
Veo Insulin Syringe	Syringe And Needle,insulin,1ml	15	suppressed
Azelastine Hcl	Azelastine Hcl	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Ozempic	Semaglutide	13	suppressed
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Glipizide Er	Glipizide	12	suppressed
Humulin N	Insulin Nph Human Isophane	12	suppressed
Duloxetine Hcl	Duloxetine Hcl	11	suppressed
Humulin R	Insulin Regular, Human	11	suppressed
Ibuprofen	Ibuprofen	11	suppressed
Naratriptan Hcl	Naratriptan Hcl	11	suppressed
Tramadol Hcl	Tramadol Hcl	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error